Is Coeptis Therapeutics Stock a Good Investment?
Coeptis Therapeutics Investment Advice | COEP |
- Examine Coeptis Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Coeptis Therapeutics' leadership team and their track record. Good management can help Coeptis Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Coeptis Therapeutics' business and its evolving consumer preferences.
- Compare Coeptis Therapeutics' performance and market position to its competitors. Analyze how Coeptis Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Coeptis Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Coeptis Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Coeptis Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Coeptis Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Coeptis Therapeutics Stock
Researching Coeptis Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.47. Coeptis Therapeutics last dividend was issued on the 6th of August 2020. The entity had 1:40000 split on the 6th of August 2020.
To determine if Coeptis Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Coeptis Therapeutics' research are outlined below:
| Coeptis Therapeutics is way too risky over 90 days horizon | |
| Coeptis Therapeutics appears to be risky and price may revert if volatility continues | |
| Coeptis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Coeptis Therapeutics currently holds 1.22 M in liabilities with Debt to Equity (D/E) ratio of 1.89, which is about average as compared to similar companies. Coeptis Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Coeptis Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (21.27 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Coeptis Therapeutics currently holds about 2.38 M in cash with (7.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 19.0% of Coeptis Therapeutics shares are held by company insiders | |
| Latest headline from gurufocus.com: Coeptis Therapeutics Secures Worldwide Development and Commercia |
Coeptis Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Coeptis Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Coeptis Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Coeptis Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Coeptis Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-28 | 2024-06-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2023-08-11 | 2023-06-30 | -0.2 | -0.1427 | 0.0573 | 28 | ||
2023-05-15 | 2023-03-31 | -0.28 | -0.39 | -0.11 | 39 | ||
2023-11-09 | 2023-09-30 | -0.01 | -0.23 | -0.22 | 2200 | ||
2023-03-29 | 2022-12-31 | -0.08 | -2.59 | -2.51 | 3137 |
Know Coeptis Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Coeptis Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Coeptis Therapeutics backward and forwards among themselves. Coeptis Therapeutics' institutional investor refers to the entity that pools money to purchase Coeptis Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Commonwealth Equity Services Inc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 0.0 | Arista Wealth Management Llc | 2024-12-31 | 0.0 | Vanguard Group Inc | 2024-12-31 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 0.0 | Meteora Capital, Llc | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 0.0 | Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 0.0 | Ubs Group Ag | 2024-12-31 | 6.8 K | Mint Tower Capital Management B.v. | 2024-12-31 | 2.2 K |
Coeptis Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.06 M.Market Cap |
|
Coeptis Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (12.13) | (11.52) | |
| Return On Capital Employed | (15.62) | (14.84) | |
| Return On Assets | (5.35) | (5.08) | |
| Return On Equity | (5.67) | (5.95) |
Determining Coeptis Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Coeptis Therapeutics is a good buy. For example, gross profit margin measures Coeptis Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Coeptis Therapeutics' profitability and make more informed investment decisions.
Evaluate Coeptis Therapeutics' management efficiency
Coeptis Therapeutics has return on total asset (ROA) of (1.8735) % which means that it has lost $1.8735 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8129) %, meaning that it created substantial loss on money invested by shareholders. Coeptis Therapeutics' management efficiency ratios could be used to measure how well Coeptis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/15/2025, Return On Tangible Assets is likely to grow to -11.52. In addition to that, Return On Capital Employed is likely to grow to -14.84. As of 03/15/2025, Non Current Liabilities Total is likely to grow to about 1.1 M, while Total Current Liabilities is likely to drop slightly above 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.03 | 0.03 | |
| Tangible Book Value Per Share | (0.06) | (0.06) | |
| Enterprise Value Over EBITDA | (22.97) | (21.82) | |
| Price Book Value Ratio | 107.38 | 102.01 | |
| Enterprise Value Multiple | (22.97) | (21.82) | |
| Price Fair Value | 107.38 | 102.01 | |
| Enterprise Value | 463 M | 439.8 M |
Coeptis Therapeutics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta (0.94) |
Basic technical analysis of Coeptis Stock
As of the 15th of March 2025, Coeptis Therapeutics shows the risk adjusted performance of 0.1635, and Mean Deviation of 8.03. Coeptis Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Coeptis Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coeptis Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coeptis Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coeptis Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coeptis Therapeutics' Outstanding Corporate Bonds
Coeptis Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coeptis Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coeptis bonds can be classified according to their maturity, which is the date when Coeptis Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Coeptis Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Coeptis Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1635 | |||
| Market Risk Adjusted Performance | (29.40) | |||
| Mean Deviation | 8.03 | |||
| Semi Deviation | 7.71 | |||
| Downside Deviation | 9.67 | |||
| Coefficient Of Variation | 564.84 | |||
| Standard Deviation | 13.96 | |||
| Variance | 194.94 | |||
| Information Ratio | 0.1841 | |||
| Jensen Alpha | 2.45 | |||
| Total Risk Alpha | 4.21 | |||
| Sortino Ratio | 0.2658 | |||
| Treynor Ratio | (29.41) | |||
| Maximum Drawdown | 93.86 | |||
| Value At Risk | (14.90) | |||
| Potential Upside | 22.28 | |||
| Downside Variance | 93.56 | |||
| Semi Variance | 59.41 | |||
| Expected Short fall | (8.56) | |||
| Skewness | 2.89 | |||
| Kurtosis | 13.45 |
| Risk Adjusted Performance | 0.1635 | |||
| Market Risk Adjusted Performance | (29.40) | |||
| Mean Deviation | 8.03 | |||
| Semi Deviation | 7.71 | |||
| Downside Deviation | 9.67 | |||
| Coefficient Of Variation | 564.84 | |||
| Standard Deviation | 13.96 | |||
| Variance | 194.94 | |||
| Information Ratio | 0.1841 | |||
| Jensen Alpha | 2.45 | |||
| Total Risk Alpha | 4.21 | |||
| Sortino Ratio | 0.2658 | |||
| Treynor Ratio | (29.41) | |||
| Maximum Drawdown | 93.86 | |||
| Value At Risk | (14.90) | |||
| Potential Upside | 22.28 | |||
| Downside Variance | 93.56 | |||
| Semi Variance | 59.41 | |||
| Expected Short fall | (8.56) | |||
| Skewness | 2.89 | |||
| Kurtosis | 13.45 |
Consider Coeptis Therapeutics' intraday indicators
Coeptis Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Coeptis Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Coeptis Therapeutics Corporate Filings
F4 | 10th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of February 2025 Other Reports | ViewVerify | |
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
S1 | 10th of January 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Coeptis Stock media impact
Far too much social signal, news, headlines, and media speculation about Coeptis Therapeutics that are available to investors today. That information is available publicly through Coeptis media outlets and privately through word of mouth or via Coeptis internal channels. However, regardless of the origin, that massive amount of Coeptis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Coeptis Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coeptis Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coeptis Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coeptis Therapeutics alpha.
Coeptis Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Coeptis Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Coeptis Therapeutics Corporate Management
| Daniel Yerace | VP CoFounder | Profile | |
| Gary Conte | VP Marketing | Profile | |
| David Mehalick | Chairman, CoFounder | Profile | |
| Brian MBA | Chief Officer | Profile | |
| MSc MD | CSO Officer | Profile |
Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.